0.000USD0.000åå ŽååŒÂ 08/03, 09:30 (ET)
504.21MæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
Ginkgo Bioworks Holdings Inc
äž»èŠããŒã¿
8.140å§å€
8.280é«å€
629.87Kåºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
--äºæ³PER
--çŽè¿12ã¶æé
åœ
1.02%売買å転ç
8.090忥çµå€
7.840å®å€
2.31M売買代é
æå€±é¡æ ªäŸ¡åçç
1.13PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-26.26%ç·è³ç£å©çç
17.58052é±é«å€
0.91åºæ¥é«æ¯ç%
-547.03MçŽå©ç
61.66Mæ ªåŒæ°
-5.34931æ ªåœããå©çïŒEPSïŒ
1.80ããŒã¿å€
-56.03%èªå·±è³æ¬å©çç
5.37052é±å®å€
5.44%æ¯ãå¹
84.09%ç²å©çç
504.21MæäŸ¡ç·é¡
-3.92ãªã¹ã¯ãªã¿ãŒã³
5.09%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-31 äž»èŠã€ã³ãµã€ã
Ginkgo Bioworks Holdings Incã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå®å®ã§ããæé·ã®å¯èœæ§ã¯é¡èã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã€ãªãã¯ãããžãŒ & å»çç ç©¶æ¥çã§ã®é äœã¯385äž150äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ãã売ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯10.00ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžéãã¬ã³ããšäºæ³ãããŸããæ ªåŒåžå Žã§ã®ããã©ãŒãã³ã¹ã¯ãã®1ãæã§éåžžã«äœèª¿ã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯å
調ã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Ginkgo Bioworks Holdings Incã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Ginkgo Bioworks Holdings Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Ginkgo Bioworks Holdings Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
Ginkgo Bioworks Holdings Inc
DNA
3
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
ææšî
ææš
売ã(3)
äžç«(2)
è²·ã(1)
ç§»åå¹³å
売ã(4)
äžç«(0)
è²·ã(2)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Ginkgo Bioworks Holdings Incã®äŒæ¥æ
å ±î
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
äŒæ¥ã³ãŒãDNA
äŒæ¥åGinkgo Bioworks Holdings Inc
æé«çµå¶è²¬ä»»è
ãCEOãKelly (Jason)
ãŠã§ããµã€ãhttps://investors.ginkgobioworks.com/
æ ªäž»çµ±èšî
ãããã質å
Ginkgo Bioworks Holdings IncïŒDNAïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îGinkgo Bioworks Holdings IncïŒDNAïŒã®çŸåšã®æ ªäŸ¡ã¯8.09ã§ãã
Ginkgo Bioworks Holdings Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îGinkgo Bioworks Holdings Incã®ãã£ãã«ãŒã·ã³ãã«ã¯DNAã§ãã
Ginkgo Bioworks Holdings Incã®52é±é«å€ã¯ãããã§ããïŒ
îGinkgo Bioworks Holdings Incã®52é±é«å€ã¯17.58ã§ãã
Ginkgo Bioworks Holdings Incã®52é±å®å€ã¯ãããã§ããïŒ
îGinkgo Bioworks Holdings Incã®52é±å®å€ã¯5.37ã§ãã
Ginkgo Bioworks Holdings Incã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îGinkgo Bioworks Holdings Incã®æäŸ¡ç·é¡ã¯504.21Mã§ãã
Ginkgo Bioworks Holdings Inc (DNA) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãGinkgo Bioworks Holdings IncïŒDNAïŒã®ç·åè©äŸ¡ã¯å£²ãã§ãç®æšæ ªäŸ¡ã¯10.00ã§ãã
Ginkgo Bioworks Holdings Inc (DNA) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îGinkgo Bioworks Holdings IncïŒDNAïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-5.64ã§ãã